New Products

Nov 09, 2018

Arima Genomics Arima-HiC Platform

Arima Genomics has announced the commercial launch of its Arima-HiC sample preparation kit. The tool allows researchers to detect long-range chromatin interactions that can be used across multiple applications. Depending on the application, researchers can generate high-quality Hi-C libraries using less than 100,000 cells across rare samples in six hours, the firm said.

Nov 08, 2018

10x Genomics Single-Cell ATAC; Feature Barcoding; Gene Expression Kits

10x Genomics has launched a number of new products. Its Single Cell ATAC Solution enables researchers to analyze open chromatin regions in single cells for epigenomic studies. The Feature Barcoding technology enables specific biological components, such as cell surface proteins or CRISPR-mediated perturbations, to be analyzed simultaneously with gene expression in the same cell. The technology is compatible with both the single-cell gene expression and immune profiling kits. In addition, the firm has launched version three of its Single Cell Gene Expression Solution, which includes enhancements to reagents, microfluidic chips, software, and visualization tools. That kit will begin shipping in December.

Nov 08, 2018

NanoString CAR-T Characterization Panel

NanoString Technologies has announced the launch of a new gene expression panel for the molecular characterization of CAR-T cells in research, development, and manufacturing of adoptive cell therapies. According to the company, the new nCounter(R) CAR-T Characterization Panel was created in collaboration with eight academic centers and is designed for use across the entirety of the CAR-T workflow including leukapheresis, manufacturing, and post-infusion monitoring.

The customizable 780-gene expression panel incorporates content to measure eight essential components of CAR-T cell biology including T-cell activation, metabolism, exhaustion, and receptor diversity with optional customization for measuring transgene expression with NanoString's Protein Barcoding Service. The firm expects to begin shipping the panel in December.

Nov 08, 2018

Hologic Panther Fusion Open Access Functionality

Hologic has introduced an Open Access functionality that will allow CLIA-certified laboratories to develop laboratory developed tests to run on its fully automated Panther Fusion platform. Labs will be able to run their LDTs simultaneously with commercially available IVD assays, and results will release automatically to laboratory information systems.

The Open Access functionality is enabled by the new myAccess software, which is designed to help laboratories create protocols, analyze data, set thresholds, and interpret results, Hologic said.

Nov 06, 2018

Biocrates Life Sciences MxP Quant 500

Biocrates Life Sciences has released its new MxP Quant 500 system. The method allows researchers to quantitatively measure a large number of different metabolites produced by intestinal bacteria, the firm said. Biocrates believes the method will provide new insights into the interaction between patients and their intestinal flora. Researchers can use the kit to determine metabolite products in blood and stool samples, including several hundreds metabolites produced by the body and substances modified by the microbiome including; choline and its degradation products, branched-chain amino acids, and secondary bile acids. 

Nov 05, 2018

Qiagen DNeasy Plant Pro Kit

Qiagen has launched the DNeasy Plant Pro Kit for extraction of high-quality DNA from varied plant samples. The new kit includes bead-beating technology for significantly higher sample disruption efficiency. Plant samples often contain high levels of secondary metabolites like polysaccharides, lipids, terpenes, or polyphenols, which are difficult to remove, Qiagen noted. To address this, the DNeasy kit also includes inhibitor removal technology to clean impurities from samples and release the DNA from masking by polyphenols.

Nov 02, 2018

Vela Diagnostics Great Basin Platform

Vela Diagnostics has commercialy launched the Great Basin infectious disease diagnostic system in Europe and the US. In preparation for the launch, Vela has relisted the products with the US and Food and Drug Administration and CE-IVD under its name. Initial site placements are evaluating the firm's Stool Bacterial Pathogens Panel. The evaluation will then be followed by Great Basin's five additional assays, including the Staph ID/R Blood Culture panel, Group B Strep Test, Shiga Toxin Direct Test, Bordetella Direct Test, and the Toxigenic C. diff test. All the assays use the Great Basin Analyzer, which is designed to perform automated sample extraction and chip-based detection in a fully enclosed cartridge with integrated data analysis.

Nov 01, 2018

Horizon Discovery Reference Standards for Biocartis Idylla MSI Assay

Horizon Discovery has launched a set of precisely defined cell line-derived reference standards to support Biocartis' recently launched Idylla microsatellite instability (MSI) Assay. The Idylla MSI Assay (RUO) allows for qualitative detection of a novel panel of seven monomorphic homopolymer biomarkers to identify human cancers with microsatellite instability, in a fully automated manner. The assay uses formalin-fixed, paraffin-embedded tissue sections from human cancer samples, and extracts, amplifies, and analyzes the nucleic acids.

Horizon's newly developed MSI FFPE reference standards, which were developed in a collaboration between the two companies, enable validation and routine monitoring of MSI testing on the Idylla platform. The reference standard material consists of a pair of FFPE sections, positive and negative for all seven MSI markers, providing a whole-process control that closely mimics a real FFPE sample. The reference standard is manufactured under ISO13485 at Horizon.

Nov 01, 2018

Agena Bioscience Chimeric ID Panel

Agena Bioscience has launched the research-use-only Chimeric ID Panel for chimerism analysis in bone marrow engraftment monitoring studies. The SNP-based panel is designed for use with the MassArray system and is accompanied by software which calculates the composition of a post-transplant follow-up specimen in seconds and displays the results in an easy-to-interpret report, the company said.

Nov 01, 2018

Veritas Genetics myGenome Premium, myGenome Diagnostic

Veritas Genetics announced it is now offering myGenome Premium and myGenome Diagnostic services, in addition to its $999 myGenome Standard service. The premium service is priced at $1,499 (or $500 for customers of the standard service) and is for those want a more indepth analysis of their carriers status, cancer risks, and cardiovascular risks. Within the premium service, customers will receive information on more than 400 genes associated with around 20 actionable conditions and on 125 genes linked to more than 200 carrier conditions. 

The $2,999 myGenome Diagnostic service ($1,999 for customers of the standard service) is for those with a personal or family history of a genetic condition, and providers interpretation of all genes known to be associated with the disease. This service is availalbe for adults and pediatric patients, and customers will also receive reports included in the standard service.

Within myGenome Standard, Veritas is also adding a new section that inlcudes "lower-impact genetic findings" associated with 15 commone diseases, for which individuals may be able to lower their risks via lifestyle changes.

Oct 31, 2018

NeuMoDx 288 and NeuMoDx 96 Molecular Systems

NeuMoDx Molecular has launched the NeuMoDx 288 Molecular System and the NeuMoDx 96 Molecular System in the US. The 288 system loads up to 288 patient samples and has been cleared by the US Food and Drug Administration, while the 96-sample instrument is registered with the FDA for lab-developed testing use. Both instruments are PCR-based and enable continuous, random-access, sample-to-results workflows for on-demand, high-throughput sample processing with an operator walkaway window of up to eight hours. The systems use the firm's proprietary NeuDry reagents which require no refrigeration and have an on-board stability of up to 60 days and room temperature shelf life of more than one year. The instrument can run NeuMoDx's growing menu of infectious disease and sexually transmitted infections assays, as well as LDTs using the company's general-purpose reagents and consumables.
Oct 31, 2018

Agilent Technologies Agilent OnePGT

Agilent Technologies has launched Agilent OnePGT, a genome-wide, next-generation sequencing solution for preimplantation genetic testing. OnePGT allows parallel detection of multiple monogenic disorders, translocations, and aneuploidies from a single biopsy, going from biopsy to a single comprehensive report in a matter of days, Agilent said. The test is run on the company's Alissa platform, allowing for automatic calling of genetic abnormalities with built-in quality control metrics and an audit trail. This solution provides fertility specialists more comprehensive PGT data in order to help them identify the most viable embryos for transfer.

Oct 31, 2018

Uromonitor Bladder Cancer Recurrence Test

Uromonitor has launched its genetic test for detecting the recurrence of bladder cancer. Also called Uromonitor, the urine-based test detects trace amounts of FGFR3 and Tert promoter mutations, which are associated with early stages of bladder cancer. Portugal's Institute of Molecular Pathology and Immunology of the University of Porto, and the Institute for Research and Innovation in Health developed the test, which is CE marked. 

Oct 30, 2018

Vela Diagnostics Sentosa SQ HCV Genotyping Assay

Vela Diagnostics has launched a new version of its Sentosa SQ HCV Genotyping Assay with improved reporting and data-interpretation features. The test uses next-generation sequencing to detect HCV genotypes 1, 2, 3, 4, 5, and 6, and subtypes 1a and 1b, and to report HCV variants in clinically relevant regions of NS3, NS5A and NS5B genes to allow drug-resistance assessment. This assay offers an integrated solution from sample to result in approximately two days with hands-on time of less than 2.5 hours.

Oct 30, 2018

Illumina TruSight Oncology 500

Illumina has launched TruSight Oncology 500 (TSO 500), a pan-cancer assay to identify known and emerging biomarkers. The assay, which is for research use only and will start shipping in the first quarter of 2019, uses both DNA and RNA from tumor samples to identify somatic variants, including small variants, gene fusions, and splice variants. It can also measure tumor mutational burden and microsatellite instability. The assay covers a large number of genes as well as 1.94 megabases of the genome to measure TMB.

Oct 30, 2018

Qiagen GeneRead QiaAct Panels and QiaSeq TMB Panel

Qiagen has launched two new GeneRead QiaAct panels for use on its GeneReader NGS System, as well as a new QiaSeq panel for use on any next-generation sequencing system to measure tumor mutational burden.

The GeneRead QiaAct Actionable Insights Tumor DNA UMI panel broadens coverage from 12 to 30 genes influencing development and progression of the most widespread cancers, including lung, melanoma, prostate and other solid tumors. The workflow targets more than 850 DNA variants in hotspot regions as well as 125 full exons.

The GeneRead QiaAct BRCA Advanced UMI panel enables analysis of the full exon coding sequences of the BRCA1, BRCA2, TP53 and PTEN genes, which play key roles in the development and progression of breast, ovarian and other cancers. The workflow will enable alignment with National Comprehensive Cancer Network guidelines on the need for comprehensive testing that encompasses full BRCA1/2 sequencing and detection of large gene rearrangements, Qiagen said.

The QiaSeq TMB Panel is designed to run on any commercial NGS platform, and the workflow targets variants in 486 genes covering full exons. In a single panel, QiaSeq TMB detects tumor mutational burden, microsatellite instability, single nucleotide variants, and indels.

Oct 30, 2018

Menarini Silicon Biosystems DepArray SamplePrep Kit

Menarini Silicon Biosystems is launching the DepArray FFPE SamplePrep Kit at the Association of Molecular Pathology annual meeting. The new kit is designed for disaggregation and staining of formalin-fixed, paraffin-embedded tissue sections down to a single-cell suspension. It enables the detection, identification, and recovery of different cell populations by the DepArray system based on specific immunofluorescent staining and DNA content, which guarantees the recovery of 100 percent pure tumor cell populations, the company said. Obtaining pure cell populations enhances downstream analysis, including next-generation sequencing and the identification of molecular targets for personalized therapies.

Oct 30, 2018

Rheonix NGS OnePrep

Rheonix has launched the NGS OnePrep solution, an integrated and automated method for DNA extraction and next-generation sequencing library preparation on the Encompass Optimum workstation. Users can now product sequence-ready libraries for up to 24 samples in 4.5 hours. The method is currently compatible with the Illumina Nextera DNA Flex Library Prep Kit but Rheonix plans to add other Illumina prep kits, as well as those from other manufacturers such as the Takara Bio Smarter ThruPlex, in the near future. Initially, the solution is compatible with buccal swab samples, saliva, fresh frozen tissue, whole blood, and bacterial isolates. Rheonix plans to include FFPE tissue and circulating cell-free DNA in coming months.

Oct 30, 2018

Cofactor Genomics ImmunoPrism Immune Profiling Kit

Cofactor Genomics launched the RNA-based ImmunoPrism Immune Profiling kit for deriving the immune composition of tumor samples, which it said has become a valuable indicator of response to immunotherapies and cancer drugs in development. The kit provides labs access to the same kit Cofactor uses to prep, sequence, and analyze against its database of machine-learing optimized immune reference expression models. 

Oct 29, 2018

Sirona Dx Oncocyst PD-L1

Sirona Dx has announced the launch of its Oncocyst PD-L1 assay. The tool uses IncellDx technology to detect and quantify abnormal bladder cells and immune cells from urine cytology specimens that express the immune-oncology marker PD-L1 using multi-parameter flow cytometry and bioinformatics. Sirona's algorithm uses aneuploidy/DNA content in cells from the bladder. Researchers can perform the high-throughput, non-subjective assay in less than three hours, the firm said.

Oct 29, 2018

DiaCarta QClamp Gene Mutation Detection Kits

DiaCarta has launched a suite of CE-IVD marked TaqMan qPCR assays using the firm's QClamp XNA-based technology. The QClamp Gene Mutation Detection Kits detect common cancer mutations in genes such as KRAS, NRAS, BRAF, EGFR, PIK3CA, and JAK2. The assays can be used on formalin-fixed, paraffin-embedded tissue biopsies as well as on cell-free DNA from liquid biopsy samples. They have been validated on the Thermo Fisher Scientific Quantstudio 5, Roche LightCycler 480, and Bio-Rad CFX384 standard real-time qPCR instruments.

Oct 26, 2018

CooperSurgical PGTai Technology Platform, ERPeak Endometrial Receptivity Test

CooperSurgical Fertility and Genomic Solutions has launched the CooperGenomics PGTai technology platform and the ERPeak endometrial receptivity test. Both will be available in North American from November 1 and internationally starting in January 2019.

The PGTai platform uses artificial intelligence and machine learning to improve the analysis, interpretation, and reporting of preimplantation genetic testing for aneuploidies (PGT-A). It is built on data from more than 1,000 biopsies that led to healthy babies. To validate the platform, the company analyzed sequencing data from more than 10,000 embryos and 5 million data points.

The ERPeak endometrial receptivity test detects the receptivity status of a woman's endometrium accurately and reliably. It measures the expression of several relevant hormone-regulated genes.

Oct 25, 2018

MGI MGISEQ-T7, MGISP-960, stLFR Library Prep Kit, MegaBolt Somatic

MGI, a subsidiary of the BGI Group, has released the MGISEQ-T7 sequencing platform. The instrument can take up to four flow cells per run, which can be operated independently of each other. The platform, which supports whole-genome sequencing, deep exome sequencing, epigenetic sequencing, and panel sequencing, generates up to 6 terabases of data per day. A run with 150-base paired-end reads takes less than 24 hours, and one instrument can sequence up to 10,000 human genomes per year.

MGI also launched the MGISP-960, an automated sample preparation system that can prepare 96 samples per run. In addition, it said that a new library preparation kit for single-tube Long Fragment Read (stLFR) technology will be commercially available in December. Finally, the company announced MegaBolt Somatic, an extended application for tumor mutation detection based on the MegaBolt bioinformatics accelerator. For more on the new BGI sequencing platform, click here.

Oct 25, 2018

Celsee Genesis Single-Cell Analysis Platform

Celsee today launched its Genesis single-cell analysis platform. The tool allows researchers to analyze and interpret cellular behavior and collect cell-based information that was previously undetectable, the firm said. Genesis uses a gentle, gravity-based method to capture and isolate individual cells while maintaining viability and structural integrity. The platform can use both liquid and tissue samples and achieves capture efficiencies of 70 percent or higher. Initial applications include proteogenomics, immune monitoring, and expansion of next-generation sequencing library preparation. 

Oct 24, 2018

SeraCare NTRK Reference Material Panel

SeraCare Life Sciences has announced the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion material panel developed in partnership with Bayer. The panel contains 15 clinically significant RNA fusions across the NTRK1, NTRK 2, and NTRK3 genes, and can be used by clinical labs to validate their detection by next-generation sequencing methods. The firm said that the RNA fusions are present within its reference cell line GM24385, and are formalin-fixed and paraffin embedded to represent typical processed tumor sections.

Pages

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.